(Press-News.org) CAMBRIDGE, Mass., February 12, 2026 - Insilico Medicine (3696.HK), a clinical-stage, generative AI-driven drug discovery company, today announced the launch of a new interactive webpage highlighting the Rentosertib story as featured in a recent Harvard Business School case study, providing a practical, public-facing overview of how AI can be applied across the drug discovery process.
The Harvard Business School case, Insilico’s Rentosertib Dilemma: A Star in the Pipeline?, examines the development of Insilico’s lead asset, Rentosertib, which completed a Phase IIa clinical evaluation for idiopathic pulmonary fibrosis (IPF). The case describes Rentosertib as the world’s first drug with both an AI-discovered target and an AI-designed molecular structure to enter Phase II human clinical trials, and uses that milestone to explore the real tradeoffs biotechs, and specifically AI-native biotech companies confront as programs move from discovery into clinical development.
Beyond the Rentosertib story, the case is written to help readers understand the broader history of Insilico Medicine as well as the rapidly innovating industry of AI-powered drug discovery. The case contextualizes the standard stages of drug development, and the cost, timelines, and attrition that shape how companies finance and manage pipelines. It also highlights how licensing agreements typically work, why many biotech companies partner with larger pharmaceutical organizations for later-stage trials and commercialization, and how emerging AI-focused companies seek to improve the speed and efficiency of early R&D while demonstrating “real-world” validation as assets reach the clinic.
“We are pleased to see Harvard Business School publish one of the first case studies that demystifies the drug discovery and development process while spotlighting a core decision many biotech companies face, whether to license or continue developing a promising asset,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “We created this resource to help a broader audience build a foundational understanding of the end-to-end workflow and the role AI can play at every step.”
Insilico’s webpage is intended to make the story easier to engage with for a broad audience, including students, operators, and biopharma teams. Despite the growing importance of AI in biotech, there are still few accessible resources built for business audiences that clearly explain the fundamentals of drug discovery, development, and the strategic tradeoffs biotech leaders face.
Structured as an “AI-Powered Drug Discovery Crash Course,” it breaks the case into a set of short modules that introduces the industry context behind the drug development efficiency challenge and the rise of AI in science, deconstructs how an AI platform can contribute across the discovery and development workflow, and walks through the Rentosertib story and the strategic questions the case is designed to provoke.
The case itself was authored by Michael Lingzhi Li PhD, Assistant Professor of Business Administration at Harvard Business School. On October 23, 2025, CEO & Founder, Alex Zhavoronkov PhD, together with senior business development leaders Suguna Rachakonda PhD and Thomas Leichner, presented the case to students from Harvard Business School’s Technology and Operations Management course.
Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.
The case is published by Harvard Business Publishing and was developed solely as a basis for classroom discussion. It is not intended to serve as an endorsement, a source of primary data, or an illustration of effective or ineffective management. Insilico’s webpage is an Insilico-authored companion intended to support learning and public understanding of the themes raised in the case and does not imply endorsement by Harvard University, Harvard Business School, or the case author.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com
END
Insilico Medicine featured in Harvard Business School case on Rentosertib
2026-02-12
ELSE PRESS RELEASES FROM THIS DATE:
Towards unlocking the full potential of sodium- and potassium-ion batteries
2026-02-12
As the world is moving towards more sustainable energy solutions, the emergence of next-generation batteries is a crucial and indispensable milestone. One such next-generation battery is the lithium-ion battery (LIB), which has been currently dominating the energy solutions sector. However, lithium is sparsely distributed across geographies, increasing extraction difficulties and battery production cost. Other next-generation batteries, such as sodium-ion batteries (NIBs) and potassium-ion batteries (KIBs), are promising alternatives to LIBs, offering resource-unconstrained, cost-effective, and sustainable ...
UC Irvine-led team creates first cell type-specific gene regulatory maps for Alzheimer’s disease
2026-02-12
NEWS
EMBARGOED UNTIL 4:00 A.M. PACIFIC TIME THURSDAY, FEB. 12, 2026
NOTE TO EDITORS: PHOTO AVAILABLE
Contact: Carly Murphy
949-501-1008
murphyco@uci.edu
Public health researchers use newly developed data analysis method to build the first cell type-specific gene regulatory maps for Alzheimer’s disease, revealing the genetic mechanisms operating within patients’ brains.
The study also identified ...
Unraveling the mystery of why some cancer treatments stop working
2026-02-12
Cancer researchers working on immunotherapies have made a big discovery: SLAMF6, a molecule on the surface of immune cells that prevents T cells from effectively attacking tumours – and, in mice, they've found a way to neutralize it.
Led by Université de Montréal medical professor Dr. André Veillette, director of the molecular oncology research unit at the UdeM-affiliated Montreal Clinical Research Institute (IRCM), the breakthrough is detailed in a study published in Nature.
An internal brake independent of tumor cells
In their lab, Veillette and his team demonstrated that, ...
From polls to public policy: how artificial intelligence is distorting online research
2026-02-12
Artificial intelligence is increasingly able to simulate human behavior and answer online surveys and political polls, putting the reliability of survey-based research at risk. Consequences can be serious not only for science and research - online surveys are a cornerstone of modern social-science research - but also for policy and participation of people in democratic processes, as surveys are widely used in political polls. This is a worry expressed in a comment in Nature by three researchers ...
Climate policy must consider cross-border pollution “exchanges” to address inequality and achieve health benefits, research finds
2026-02-12
Ambitious climate action to improve global air quality could save up to 1.32 million lives per year by 2040, according to a new study.
The research, led by Cardiff University, shows how developing countries rely heavily on international cooperation to see these benefits, because much of their pollution originates outside their borders.
The first-of-its-kind study analysed these cross-border pollution “exchanges” for nearly every country – 168 in total.
Their findings, published in Nature Communications, reveal how a fragmented world, with little collaborative climate mitigation policymaking, would lead ...
What drives a mysterious sodium pump?
2026-02-12
Kyoto, Japan -- The enzyme Na⁺-NQR is a sodium pump that drives the respiration of many marine and pathogenic bacteria. Using redox reactions, the process of exchanging electrons between materials, it powers the transportation of sodium ions across the membrane, supporting the growth of the bacteria.
Yet there is a mystery behind this mechanism, as scientists have had trouble understanding exactly how the redox reactions are linked to sodium-pumping. In particular, the lack of structural information on the key intermediate states that form while the enzyme is operating has posed a major challenge; determining these structures is essential to understanding how the ...
Study reveals new cellular mechanisms that allow the most common chronic cardiac arrhythmia to persist in the heart
2026-02-12
Atrial fibrillation (AF), the most common chronic cardiac arrhythmia in clinical practice, is very challenging to treat once it becomes persistent, after which spontaneous return to normal rhythm becomes highly unlikely. A multidisciplinary study led by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and published in Circulation Research now provides a new perspective on why this arrhythmia can persist long-term, highlighting the key role of non-contractile cardiac cells.
AF has traditionally been viewed as a purely electrical disorder of cardiomyocytes—the heart’s contractile cells. However, the ...
Scientists discover new gatekeeper cell in the brain
2026-02-12
Ghent, 12 February 2026 – VIB and Ghent University researchers have identified and characterized a previously unknown cellular barrier in the brain, which sheds new light on how the brain is protected from the rest of the body. In a study published in Nature Neuroscience, the scientists also reveal a new pathway by which the immune system can impact the brain.
Prof. Roosmarijn Vandenbroucke (VIB–UGent Center for Inflammation Research): “These findings reveal how vulnerable and protectable the brain is, opening new perspectives for more targeted interventions in brain disorders.”
The ...
High blood pressure: trained laypeople improve healthcare in rural Africa
2026-02-12
In rural regions of Africa, high blood pressure often goes untreated because health centres are far away and there is a shortage of health professionals. A study in Lesotho shows that, with the help of a tablet app, villagers who have received training achieve better blood pressure control in their village community compared to normal treatment in healthcare facilities. The results provide the first robust data for an approach that could significantly improve access to blood pressure treatment in underserved regions. ...
Pitt research reveals protective key that may curb insulin-resistance and prevent diabetes
2026-02-12
Scientists at the University of Pittsburgh School of Medicine discovered a surprising new way the body can fight insulin resistance and diabetes – by boosting a special type of “good” immune cell in fat tissue.
Announced today in Nature Communications, the preclinical findings pave the path to develop a medication to treat and prevent type 2 diabetes, potentially replacing or supplementing GLP-1 weight maintenance drugs that lose effectiveness over time.
“One-third of our population is obese or overweight – over the next decade or so, ...